Avita to raise $13M+ for regenerative burn treatment

Avita's device allows a healthcare provider to quickly harvest cells from a skin sample, which are then used to create a suspension for the treatment of a burn or wound.

Avita Medical is looking to raise AU$16.9 million ($13.2 million) to carry its cell-harvesting device—which allows healthcare providers to quickly regenerate skin for burn treatment—through FDA submission and a U.S. launch.

The company, which maintains officers in Perth, Australia, London and Valencia, California, has already secured AU$4.5 million ($3.5 million) in a private placement, according to a statement.

“We sincerely appreciate the support received from investors under the Private Placement, indicating confidence in Avita’s pursuit of its future milestones, including PMA approval in 2018 followed by a successful commercial launch of ReCell in the US burns market,” said Avita CEO Mike Perry, in the statement.


Share your opinion. Take our five minute survey.

How do you select the most suitable advanced dosage forms for new molecules in your development pipelines? Share your insights in this 5-minute survey. The first 50 qualified respondents will receive a $5 Amazon gift card.

“This fund raising is expected to underpin Avita through key milestones including, initial BARDA product procurement, U.S. FDA approval, and the launch of ReCell in the US burns market,” Perry added.

The ReCell Autologous Cell Harvesting device is a single-use device that enables a medical professional to collect cells from a sample of the patient’s skin. The cells are then used to create a suspension that can be used in wound and burn treatment.

Avita scored $16.9 million up front from the U.S. Biomedical Advanced Research and Development Authority (BARDA) in October 2015, to back the PMA approval trial of the burn treatment, dubbed ReCell. As part of the deal, Avita stood to win an additional $37 million in contract options. In September, the pair executed (PDF) a $23.4 million option and extended their contract through September 2022.

Burns are typically treated with skin grafts, but these can be unsuitable for large burns that need substantial coverage. A regenerative approach could plug this gap. Salt Lake City-based PolarityTE recently launched SkinTE, its platform that regenerates full-thickness skin.

Suggested Articles

A phase 3 study of NuCana’s lead drug was halted because a monitoring committee deemed it unlikely to succeed.

The National Institutes of Health has tapped the genomics firm Color to help participants understand and act on their results.

In a $72 million deal, Inex Innovations Exchange and Nova Satra will combine their laboratory, R&D and distribution arms.